Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Ovid Therapeutics Inc. reported revenue of $7M, up 1181.3% year over year. Operating margin was -585.2% and net margin -240.1%, on a free-cash-flow margin of -528.6% with capital expenditure at 0.0% of revenue. Every figure is computed directly from OVID's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $7M | -585.2% | -240.1% |
| FY2024 | $1M | -10933.7% | -4670.1% |
| FY2023 | $0M | -15122.7% | -13351.8% |
| FY2022 | $2M | -3696.4% | -3604.7% |
| FY2021 | $208M | 59.6% | 58.9% |
How does OVID compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.